MX384240B - Bacterias probioticas recombinantes. - Google Patents

Bacterias probioticas recombinantes.

Info

Publication number
MX384240B
MX384240B MX2017010150A MX2017010150A MX384240B MX 384240 B MX384240 B MX 384240B MX 2017010150 A MX2017010150 A MX 2017010150A MX 2017010150 A MX2017010150 A MX 2017010150A MX 384240 B MX384240 B MX 384240B
Authority
MX
Mexico
Prior art keywords
probiotic bacteria
recombinant probiotic
recombinant
inflammatory skin
skin dysfunction
Prior art date
Application number
MX2017010150A
Other languages
English (en)
Other versions
MX2017010150A (es
Inventor
Dirk Weber
Haritha Samaranayake
Herwig Bachmann
Igor Mierau
JUHA YRJäNHEIKKI
Peter Allard Bron
Thomas Wirth
Original Assignee
Aurealis Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurealis Oy filed Critical Aurealis Oy
Publication of MX2017010150A publication Critical patent/MX2017010150A/es
Publication of MX384240B publication Critical patent/MX384240B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a bacterias probióticas recombinantes, especialmente para uso en el tratamiento de una disfunción inflamatoria de la piel, así como un método para tratar una disfunción inflamatoria de la piel.
MX2017010150A 2015-02-04 2015-11-02 Bacterias probioticas recombinantes. MX384240B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2015/052345 WO2016124239A1 (en) 2015-02-04 2015-02-04 Recombinant probiotic bacteria for use in the treatment of a skin dysfunction
PCT/EP2015/075484 WO2016124266A1 (en) 2015-02-04 2015-11-02 Recombinant probiotic bacteria

Publications (2)

Publication Number Publication Date
MX2017010150A MX2017010150A (es) 2018-06-15
MX384240B true MX384240B (es) 2025-03-14

Family

ID=53039847

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010150A MX384240B (es) 2015-02-04 2015-11-02 Bacterias probioticas recombinantes.

Country Status (27)

Country Link
US (1) US10738315B2 (es)
EP (1) EP3253402B1 (es)
JP (1) JP6726419B2 (es)
KR (1) KR102172228B1 (es)
CN (1) CN107438666B (es)
AU (1) AU2015381262B2 (es)
CA (1) CA2975636C (es)
CY (2) CY20182200002T2 (es)
DE (1) DE15821025T8 (es)
DK (1) DK3253402T3 (es)
ES (1) ES2673007T3 (es)
HR (1) HRP20200973T1 (es)
HU (1) HUE050790T2 (es)
IL (1) IL253782B (es)
LT (1) LT3253402T (es)
MX (1) MX384240B (es)
NZ (1) NZ734579A (es)
PL (1) PL3253402T3 (es)
PT (1) PT3253402T (es)
RS (1) RS60437B1 (es)
RU (1) RU2723324C2 (es)
SG (1) SG11201706398VA (es)
SI (1) SI3253402T1 (es)
SM (1) SMT202000344T1 (es)
TR (1) TR201808169T3 (es)
WO (2) WO2016124239A1 (es)
ZA (1) ZA201705812B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081493B1 (ko) 2014-12-23 2020-02-26 일리야 팔마 에이비 상처 치유 방법
IL265177B2 (en) 2016-09-13 2025-01-01 Intrexon Actobiotics N V A microorganism that adheres to the mucosa
US12121573B2 (en) 2019-07-14 2024-10-22 Tianxin Wang Methods and agents including STING agonist to treat tumor
WO2019113023A1 (en) * 2017-12-04 2019-06-13 The BioCollective, LLC Probiotics and methods of use
US11918825B2 (en) 2018-02-24 2024-03-05 Clearskin Ltd. Compositions, devices, systems, kits and methods for the treatment of a skin condition
US20230240348A1 (en) * 2018-06-19 2023-08-03 Coenbio Co., Ltd. Composition for improving liver function comprising leuconostoc sp. strain
WO2019245225A1 (ko) * 2018-06-19 2019-12-26 (주)코엔바이오 류코노스톡속 균주를 포함하는 장 기능 개선용 조성물
KR102173168B1 (ko) * 2018-06-19 2020-11-03 주식회사 엠디헬스케어 류코노스톡속 균주를 포함하는 장 기능 개선용 조성물
KR102283127B1 (ko) * 2018-06-19 2021-07-29 주식회사 엠디헬스케어 류코노스톡속 균주를 포함하는 간 기능 개선용 조성물
WO2020031204A1 (en) * 2018-08-08 2020-02-13 Sree Chitra Tirunal Institute For Medical Science And Technology Recombinant tgf α for wound healing purposes, and the process thereof
CN109078171A (zh) * 2018-09-10 2018-12-25 因之彩生物科技（武汉）有限公司 一种外用组合物及其应用以及外用治疗剂
IT201900003115A1 (it) * 2019-03-04 2020-09-04 Univ Degli Studi Roma La Sapienza Lattococco ingegnerizzato
BR112021017547A2 (pt) * 2019-03-04 2021-11-09 Celloryx AG Bactéria recombinante, ácido nucleico recombinante, dispositivo médico, composição farmacêutica, kit para uso em medicina e uso de um meio de reconstituição
BR112021023682A2 (pt) * 2019-06-24 2022-04-12 Mendes Srl Composição com ação antibacteriana e de reepitelização incluindo probióticos
CN112175890A (zh) * 2019-07-02 2021-01-05 深伦生物科技（深圳）有限公司 一种以食用菌分泌乙醇脱氢酶的基因工程菌
KR102343938B1 (ko) * 2020-09-02 2021-12-28 주식회사 비피도 재조합 비피도박테리움 비피덤 bgn4를 포함하는 염증 개선용 조성물
CN112359049B (zh) * 2020-12-10 2022-01-28 昆明理工大学 一种岷江百合几丁质酶基因LrCHI2及其应用
KR102253283B1 (ko) * 2020-12-21 2021-05-18 주식회사 비피도 비피도박테리움 비피덤을 이용한 인간 egf 단백질의 생산방법 및 이를 함유하는 조성물
EP4301384A4 (en) * 2021-03-05 2024-10-02 The Regents of the University of California SKIN PROBIOTICS
KR102809763B1 (ko) * 2021-12-06 2025-05-20 주식회사 바이오에프디엔씨 세포 투과형 성장인자를 포함하는 세포 배양 또는 증식을 위한 조성물
CN114395514B (zh) * 2022-02-28 2023-09-01 鲁东大学 一株嗜酸乳杆菌、菌剂及其应用
KR102838081B1 (ko) * 2022-04-12 2025-07-24 고려대학교 산학협력단 마이크로바이옴을 이용하여 당뇨족부궤양 예후를 예측하는 방법
CN114957437B (zh) * 2022-06-06 2023-03-21 陕西理工大学 一种leap-2重组蛋白和一种重组乳酸乳球菌及其应用
CN115181710B (zh) * 2022-09-13 2022-11-25 北京量化健康科技有限公司 一株唾液乳杆菌b12wu及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101052705A (zh) 2004-05-18 2007-10-10 佛兰芒语埋葬－大学生物技术研究所Vzw 自身遏制性乳杆菌菌株
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
ES2595729T3 (es) 2007-01-12 2017-01-03 Intrexon Actobiotics Nv Promotores de Lactococcus y usos de los mismos
CA2689658A1 (en) * 2007-06-20 2008-12-24 Actogenix Nv Methods and compositions for treating mucositis
US8236527B2 (en) * 2008-03-14 2012-08-07 Humanzyme Limited Recombinant production of authentic human proteins using human cell expression systems
CN105671027A (zh) * 2008-09-30 2016-06-15 诺维信股份有限公司 在丝状真菌细胞中使用阳性和阴性选择性基因的方法
US20100247461A1 (en) * 2009-01-20 2010-09-30 Signum Biosciences, Inc. Anti-inflammatory complexes
CN102209701B (zh) 2008-11-11 2014-10-15 西格纳姆生物科学公司 异戊二烯基化合物和其方法
FR2948868B1 (fr) * 2009-08-07 2011-10-07 Anthogyr Sa Piece a main a moyens de connexion electrique
EP2451467B1 (en) 2010-01-14 2016-12-21 INSERM - Institut National de la Santé et de la Recherche Médicale Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (ibd) and irritable bowel syndrome (ibs)
US20130078275A1 (en) * 2010-05-25 2013-03-28 The Board Of Trustees Of The University Of Illinois Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells
CN103189504B (zh) * 2010-06-18 2017-05-24 北卡罗莱纳州立大学 减少炎性反应的具有减少的脂磷壁酸的重组乳杆菌
CN101892189B (zh) * 2010-07-05 2012-07-04 浙江大学 一种口服免疫阻断猪生长抑素作用的转化子及其应用
JP2012019768A (ja) * 2010-07-16 2012-02-02 Osaka Univ Ｊｍｊｄ３遺伝子改変非ヒト哺乳動物、Ｊｍｊｄ３遺伝子改変骨髄キメラ非ヒト哺乳動物、及びその利用
TWI566701B (zh) 2012-02-01 2017-01-21 日本農藥股份有限公司 芳烷氧基嘧啶衍生物及包含該衍生物作為有效成分的農園藝用殺蟲劑及其使用方法
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
TWI613833B (zh) 2012-11-09 2018-02-01 Sony Corp 光電變換元件、固體攝像裝置及電子機器
CA2890034A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
CA2950945A1 (en) 2014-06-17 2015-12-23 Xycrobe Therapeutics, Inc. Genetically modified bacteria and methods for genetic modification of bacteria

Also Published As

Publication number Publication date
EP3253402A1 (en) 2017-12-13
CN107438666B (zh) 2021-08-17
ES2673007T3 (es) 2021-01-22
PL3253402T3 (pl) 2021-02-08
SG11201706398VA (en) 2017-09-28
US20180135062A1 (en) 2018-05-17
RS60437B1 (sr) 2020-07-31
HUE15821025T1 (hu) 2018-12-28
TR201808169T3 (tr) 2018-07-23
CN107438666A (zh) 2017-12-05
US10738315B2 (en) 2020-08-11
AU2015381262A1 (en) 2017-08-17
ZA201705812B (en) 2019-12-18
CY20182200002T2 (el) 2018-09-05
KR102172228B1 (ko) 2020-11-02
RU2723324C2 (ru) 2020-06-09
MX2017010150A (es) 2018-06-15
CY1123065T1 (el) 2021-10-29
LT3253402T (lt) 2020-06-10
IL253782A0 (en) 2017-09-28
RU2017127991A3 (es) 2019-03-04
WO2016124266A1 (en) 2016-08-11
JP2018509932A (ja) 2018-04-12
IL253782B (en) 2022-04-01
EP3253402B1 (en) 2020-04-29
SI3253402T1 (sl) 2020-08-31
CA2975636A1 (en) 2016-08-11
HUE050790T2 (hu) 2021-01-28
DK3253402T3 (da) 2020-06-02
WO2016124239A1 (en) 2016-08-11
DE15821025T8 (de) 2018-09-13
NZ734579A (en) 2019-10-25
JP6726419B2 (ja) 2020-07-22
AU2015381262B2 (en) 2019-03-28
RU2017127991A (ru) 2019-03-04
BR112017016772A2 (pt) 2018-04-17
SMT202000344T1 (it) 2020-07-08
KR20170118772A (ko) 2017-10-25
HRP20200973T1 (hr) 2020-10-02
CA2975636C (en) 2022-12-06
ES2673007T1 (es) 2018-06-19
PT3253402T (pt) 2020-07-07
DE15821025T1 (de) 2018-07-26
DK3253402T1 (da) 2018-06-18

Similar Documents

Publication Publication Date Title
MX384240B (es) Bacterias probioticas recombinantes.
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
PH12016501978B1 (en) Treatment of nafld and nash
MX2021010460A (es) Metodo de tratamiento con tradipitant.
EA201991997A1 (ru) Комбинированная терапия
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
EA201692284A1 (ru) Ниацинамид для стимуляции продуцирования антимикробных пептидов
SG10201804034QA (en) Methods for treating hypotension
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
PH12019500725A1 (en) Methods of treating acute kidney injury
TW201613587A (en) Medical treatments based on anamorelin
MX2016005393A (es) Metodos para tratar vhc.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
ZA201703467B (en) Methods of treating ocular conditions
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2018011379A (es) Tratamiento del prurito uremico.
PL3322480T3 (pl) Bakterie Lactobacillus w leczeniu zaburzeń czynności serca
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
UA108151U (uk) Спосіб обробки шкір